FDA approves Zemdri for UTIs but not bloodstream infections

The US FDA has approved Zemdri (plazomicin) for use in adults with complicated urinary tract infections (cUTIs) caused by certain Enterobacteriaceae. However, it isn’t all good news as the agency has also issued a response for bloodstream infections, noting there isn’t substantial evidence of Zemdri’s effectiveness.

To view restricted content, please:

Register FREE

Login

Antibiotics Drug Development Industry